PE20120998A1 - Metodos para el tratamiento del cancer usando antagonistas de notch - Google Patents
Metodos para el tratamiento del cancer usando antagonistas de notchInfo
- Publication number
- PE20120998A1 PE20120998A1 PE2012000413A PE2012000413A PE20120998A1 PE 20120998 A1 PE20120998 A1 PE 20120998A1 PE 2012000413 A PE2012000413 A PE 2012000413A PE 2012000413 A PE2012000413 A PE 2012000413A PE 20120998 A1 PE20120998 A1 PE 20120998A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- methods
- treating cancer
- cdr
- heavy
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003540 gamma secretase inhibitor Substances 0.000 abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 208000000389 T-cell leukemia Diseases 0.000 abstract 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 abstract 1
- 208000003747 lymphoid leukemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UN METODO DE TRATAMIENTO DE LEUCEMIA DE CELULAS T TAL COMO LEUCEMIA LINFOBLASTICA SENSIBLE A LOS INHIBIDORES DE LA GAMMA-SECRETASA (GSI), EL CUAL COMPRENDE ADMINISTRAR A UN PACIENTE i) UNA CANTIDAD DE UN ANTAGONISTA DE Notch3 QUE ES UN ANTICUERPO ANTI-Notch3 NRR QUE COMPRENDE LAS CDR DE LA REGION VARIABLE DE LA CADENA PESADA Y LIGERA DEL ANTICUERPO 256A-4 O 256A-8, Y ii) UNA CANTIDAD DE UN ANTAGONISTA DE Notch1 QUE ES UN ANTICUERPO ANTI-Notch1 NRR QUE COMPRENDE LAS CDR DE LA REGION VARIABLE DE LA CADENA PESADA Y LIGERA DEL ANTICUERPO A, A-1, A-2 O A-3. TAMBIEN SE REFIERE A UN METODO PARA LA IDENTIFICACION DE UN CANCER ADECUADO PARA EL TRATAMIENTO CON UN ANTAGONISTA DE Notch3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24729809P | 2009-09-30 | 2009-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120998A1 true PE20120998A1 (es) | 2012-08-14 |
Family
ID=43127684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000413A PE20120998A1 (es) | 2009-09-30 | 2010-09-29 | Metodos para el tratamiento del cancer usando antagonistas de notch |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9200071B2 (es) |
| EP (1) | EP2483311B1 (es) |
| JP (3) | JP6025563B2 (es) |
| KR (1) | KR101782180B1 (es) |
| CN (1) | CN102630229B (es) |
| AU (1) | AU2010300747A1 (es) |
| BR (1) | BR112012007252A2 (es) |
| CA (1) | CA2775880A1 (es) |
| CL (1) | CL2012000800A1 (es) |
| CO (1) | CO6531430A2 (es) |
| CR (1) | CR20120213A (es) |
| EC (1) | ECSP12011858A (es) |
| ES (1) | ES2580229T3 (es) |
| HK (1) | HK1170505A1 (es) |
| IL (1) | IL218662A0 (es) |
| MA (1) | MA33973B1 (es) |
| MX (1) | MX342250B (es) |
| PE (1) | PE20120998A1 (es) |
| PH (1) | PH12012500574A1 (es) |
| RU (1) | RU2012117619A (es) |
| WO (1) | WO2011041336A2 (es) |
| ZA (1) | ZA201201984B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539403A (ja) | 2006-06-13 | 2009-11-19 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断および処置するための組成物および方法 |
| WO2008091641A2 (en) | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| EP2899211A1 (en) | 2008-07-08 | 2015-07-29 | OncoMed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| JP6059985B2 (ja) | 2009-06-18 | 2017-01-11 | ファイザー・インク | 抗ｎｏｔｃｈ−１抗体 |
| KR101580726B1 (ko) | 2010-12-15 | 2015-12-29 | 와이어쓰 엘엘씨 | 항-노치1 항체 |
| TW201431880A (zh) | 2012-11-07 | 2014-08-16 | Pfizer | 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體 |
| PL2935330T3 (pl) | 2012-12-19 | 2019-11-29 | Aveo Pharmaceuticals Inc | Przeciwciała przeciw notch3 |
| WO2014159242A1 (en) * | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
| CN105246916A (zh) * | 2013-03-14 | 2016-01-13 | 诺华股份有限公司 | 针对notch 3的抗体 |
| US20160030561A1 (en) * | 2013-03-15 | 2016-02-04 | Oncomed Pharmaceuticals, Inc. | Methods of Treating Pancreatic Cancer |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| TR201810635T4 (tr) * | 2014-02-12 | 2018-08-27 | Hoffmann La Roche | Anti-jagged1 antikorları ve kullanım yöntemleri. |
| US9914774B2 (en) | 2014-07-11 | 2018-03-13 | Genentech, Inc. | Notch pathway inhibition |
| CN105585636B (zh) * | 2015-11-24 | 2020-03-03 | 南方医科大学 | 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用 |
| EP3448420B1 (en) | 2016-04-29 | 2022-09-14 | Aveo Pharmaceuticals, Inc. | Anti-notch3 antibody |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0710719B1 (en) | 1990-01-12 | 2007-03-14 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
| CA2312208C (en) | 1997-12-05 | 2011-01-25 | The Scripps Research Institute | Humanization of murine antibody |
| AU2005323025A1 (en) | 2004-12-31 | 2006-07-13 | Biogen Idec Ma Inc. | Polypeptides that bind BR3 and uses thereof |
| BRPI0715989A8 (pt) | 2006-10-19 | 2018-03-13 | Genentech Inc | "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" |
| PE20080891A1 (es) * | 2006-10-19 | 2008-08-25 | Genentech Inc | Anticuerpos anti-notch3 y composiciones que los comprenden |
| JP5386364B2 (ja) | 2006-12-18 | 2014-01-15 | ジェネンテック， インコーポレイテッド | 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用 |
| WO2008091641A2 (en) * | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP2134356A2 (en) * | 2007-03-05 | 2009-12-23 | Board of Regents, The University of Texas System | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| EP2899211A1 (en) * | 2008-07-08 | 2015-07-29 | OncoMed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
| WO2010141249A2 (en) * | 2009-06-02 | 2010-12-09 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-notch3 antibodies |
| JP6059985B2 (ja) * | 2009-06-18 | 2017-01-11 | ファイザー・インク | 抗ｎｏｔｃｈ−１抗体 |
-
2010
- 2010-09-29 EP EP10762827.3A patent/EP2483311B1/en active Active
- 2010-09-29 PH PH1/2012/500574A patent/PH12012500574A1/en unknown
- 2010-09-29 MA MA34797A patent/MA33973B1/fr unknown
- 2010-09-29 CN CN201080054108.9A patent/CN102630229B/zh active Active
- 2010-09-29 BR BR112012007252-8A patent/BR112012007252A2/pt not_active IP Right Cessation
- 2010-09-29 US US13/498,560 patent/US9200071B2/en active Active
- 2010-09-29 CA CA2775880A patent/CA2775880A1/en not_active Abandoned
- 2010-09-29 JP JP2012532248A patent/JP6025563B2/ja active Active
- 2010-09-29 WO PCT/US2010/050610 patent/WO2011041336A2/en active Application Filing
- 2010-09-29 ES ES10762827.3T patent/ES2580229T3/es active Active
- 2010-09-29 MX MX2012003851A patent/MX342250B/es active IP Right Grant
- 2010-09-29 RU RU2012117619/10A patent/RU2012117619A/ru not_active Application Discontinuation
- 2010-09-29 PE PE2012000413A patent/PE20120998A1/es not_active Application Discontinuation
- 2010-09-29 AU AU2010300747A patent/AU2010300747A1/en not_active Abandoned
- 2010-09-29 KR KR1020127010886A patent/KR101782180B1/ko not_active Expired - Fee Related
-
2012
- 2012-03-15 IL IL218662A patent/IL218662A0/en unknown
- 2012-03-16 ZA ZA2012/01984A patent/ZA201201984B/en unknown
- 2012-03-30 CL CL2012000800A patent/CL2012000800A1/es unknown
- 2012-04-09 CO CO12057624A patent/CO6531430A2/es not_active Application Discontinuation
- 2012-04-26 CR CR20120213A patent/CR20120213A/es unknown
- 2012-04-30 EC ECSP12011858 patent/ECSP12011858A/es unknown
- 2012-11-08 HK HK12111268.8A patent/HK1170505A1/xx unknown
-
2015
- 2015-01-23 JP JP2015011573A patent/JP2015145362A/ja not_active Withdrawn
-
2016
- 2016-07-13 JP JP2016138236A patent/JP2017014219A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013506675A (ja) | 2013-02-28 |
| RU2012117619A (ru) | 2013-11-10 |
| US20120328608A1 (en) | 2012-12-27 |
| CN102630229B (zh) | 2015-03-04 |
| EP2483311B1 (en) | 2016-05-18 |
| ZA201201984B (en) | 2013-05-29 |
| CR20120213A (es) | 2012-07-09 |
| MX342250B (es) | 2016-09-22 |
| MX2012003851A (es) | 2012-05-08 |
| KR101782180B1 (ko) | 2017-10-23 |
| KR20120100952A (ko) | 2012-09-12 |
| CL2012000800A1 (es) | 2012-08-31 |
| WO2011041336A2 (en) | 2011-04-07 |
| HK1170505A1 (en) | 2013-03-01 |
| JP6025563B2 (ja) | 2016-11-16 |
| PH12012500574A1 (en) | 2012-10-22 |
| ECSP12011858A (es) | 2012-06-29 |
| BR112012007252A2 (pt) | 2020-08-11 |
| MA33973B1 (fr) | 2013-02-01 |
| JP2017014219A (ja) | 2017-01-19 |
| AU2010300747A1 (en) | 2012-04-26 |
| ES2580229T3 (es) | 2016-08-22 |
| CO6531430A2 (es) | 2012-09-28 |
| JP2015145362A (ja) | 2015-08-13 |
| CN102630229A (zh) | 2012-08-08 |
| WO2011041336A3 (en) | 2012-05-03 |
| EP2483311A2 (en) | 2012-08-08 |
| CA2775880A1 (en) | 2011-04-07 |
| US9200071B2 (en) | 2015-12-01 |
| IL218662A0 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120998A1 (es) | Metodos para el tratamiento del cancer usando antagonistas de notch | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR054566A1 (es) | Tratamientoombinado de los tumores que expresan el her | |
| MX2016007972A (es) | Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos. | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
| CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
| CO6410298A2 (es) | Pirimidinas fusionadas | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| UY33221A (es) | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| ECSP11011405A (es) | Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |